V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Vertex Pharmaceuticals Executive Compensation (FY25)

VRTX · Boston, MA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Reshma Kewalramani
Median of the other named officers
$6,974,920
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 13, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Vertex Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 13, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Vertex Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
334 figures on this page: 327 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Reshma Kewalramani: $21,538,668 → $21,144,261 (1.8% lower)
Say-on-pay support: 92.5% → 93.5% (1.0 points higher)
CEO pay ratio: 88:1 → 80:1 (9.1% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Vertex Pharmaceuticals' chief executive and what were they paid?
Total compensation for Reshma Kewalramani, Chief Executive Officer and President, came to $21,144,261 in fiscal 2025. Kewalramani's total was 1.8% lower than the $21,538,668 reported for fiscal 2024.
What was Vertex Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 93.5% of votes cast for or against in favor at the meeting held May 13, 2026 for fiscal 2025.
Which companies are in Vertex Pharmaceuticals' peer group?
Companies named in the disclosed peer group include AbbVie Inc., Amgen, Inc., Biogen, Inc., Bristol-Myers Squibb Company and Eli Lilly and Company, among others.
What is Vertex Pharmaceuticals' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 80:1, against median employee compensation of $264,487.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Reshma Kewalramani
Chief Executive Officer and President
◇—◇—◇—◇◇
Stuart Arbuckle
Executive Vice President and Chief Operating Officer
◇—◇—◇—◇◇
Jeffrey Leiden
Executive Chairman
——◇———◇◇
David Altshuler
Executive Vice President and Chief Scientific Officer
◇—◇—◇—◇◇
Charles Wagner
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Reshma Kewalramani
Chief Executive Officer and President
◇—◇—◇—◇◇
Stuart Arbuckle
Executive Vice President and Chief Operating Officer
◇—◇—◇—◇◇
Charles Wagner
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Jeffrey Leiden
Executive Chairman
——◇———◇◇
David Altshuler
Executive Vice President and Chief Scientific Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Reshma Kewalramani
CEO and President
◇—◇—◇—◇◇
Stuart Arbuckle
EVP & Chief Operating Officer
◇—◇—◇—◇◇
Charles Wagner
EVP & Chief Financial Officer
◇—◇—◇—◇◇
David Altshuler
EVP & Chief Scientific Officer
◇—◇—◇—◇◇
Nia Tatsis
EVP & Chief Regulatory and Quality Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Reshma Kewalramani
Chief Executive Officer and President
◇—◇—◇—◇◇
Stuart Arbuckle
Former Executive Vice President, Chief Operating Officer
Departed during or after this year
◇—◇———◇◇
Charles Wagner
Executive Vice President, Chief Operating and Financial Officer
◇—◇—◇—◇◇
Nia Tatsis
Executive Vice President, Chief Regulatory and Quality Officer
◇—◇—◇—◇◇
Amit Sachdev
Executive Vice President, Chief Patient and External Affairs Officer
◇—◇—◇—◇◇
Carmen Bozic
Executive Vice President, Chief Medical Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Amit SachdevPSU◇—◇—◇—◇
Amit SachdevPSU◇——◇——◇
Amit SachdevRSU◇——◇——◇
Carmen BozicPSU◇—◇—◇—◇
Carmen BozicPSU◇——◇——◇
Carmen BozicRSU◇——◇——◇
Charles WagnerPSU◇—◇—◇—◇
Charles WagnerPSU◇——◇——◇
Charles WagnerRSU◇——◇——◇
Nia TatsisPSU◇—◇—◇—◇
Nia TatsisRSU◇——◇——◇
Nia TatsisPSU◇——◇——◇
Reshma KewalramaniPSU◇—◇—◇—◇
Reshma KewalramaniPSU◇——◇——◇
Reshma KewalramaniRSU◇——◇——◇
Stuart ArbucklePSU◇—◇—◇—◇
Stuart ArbucklePSU◇——◇——◇
Stuart ArbucklePSU◇——◇——◇
Stuart ArbuckleRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Reshma KewalramaniRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Amit SachdevRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Stuart ArbuckleRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Charles WagnerRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Carmen BozicRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Nia TatsisRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Charles Wagner
Executive Vice President, Chief Operating and Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bruce I. Sachs
Lead independent director
◇—◇——◇◇
Suketu Upadhyay
◇◇———◇◇
Lloyd Carney
◇◇———◇◇
Sangeeta N. Bhatia
◇◇———◇◇
Diana McKenzie
◇◇———◇◇
Alan Garber
◇◇◇——◇◇
Michel Lagarde
◇—◇——◇◇
Jennifer Schneider
◇◇———◇◇
Nancy Thornberry
◇◇◇——◇◇
Jeffrey Leiden and Reshma Kewalramani served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Amgen, Inc. AMGN
  • Biogen, Inc. BIIB
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences, Inc. GILD
  • Incyte Corporation INCY
  • Jazz Pharmaceuticals plc JAZZ
  • Moderna, Inc. MRNA
  • Regeneron Pharmaceuticals, Inc. REGN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 13, 2026=◇◇◇
2024May 14, 2025=◇◇◇
2023May 15, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 18, 2022=◇◇◇
2020May 19, 2021=◇◇◇
2019June 3, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Reshma Kewalramani (Chief Executive Officer and President), FY2025 total compensation $21,144,261 (base salary $1,600,000) [exec_comp, SEC accession 0000875320-26-000153, filed 2026-04-02]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Vertex Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Vertex Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Vertex Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Vertex Pharmaceuticals' disclosed peer group is defensible, who names Vertex Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
334 figures on this page: 327 cited to the filing that reported them, 7 calculated from figures it prints.
327 cited to the filing
7 calculated from the filing

Documents cited

  1. 0000875320-26-000204
    Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers: For Against Abstain Non-Vote
  2. 0000875320-26-000153
    Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards During · Outstanding Equity Awards at Fiscal Year-End for · and 2 more sections
  3. 0000875320-25-000194
    Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the Company's named executive officers: For Against Abstain Non-Vote
  4. 0000875320-25-000160
    Summary Compensation Table
  5. 0000875320-24-000142
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001308179-24-000452
    Summary Compensation Table
  7. 0000875320-23-000015
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001308179-23-000591
    Summary Compensation Table
  9. 0001193125-22-154021
  10. 0000875320-21-000018
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0000875320-20-000023
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Vertex Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/VRTX (accessed 2026).
Short form: data: Velarion

The Vertex Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Vertex Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Vertex Pharmaceuticals discloses

The companies named in VRTX's own disclosed peer group.

AbbVie Inc.Amgen, Inc.Biogen, Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyGilead Sciences, Inc.Incyte CorporationJazz Pharmaceuticals plcModerna, Inc.Regeneron Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy